Atezolizumab, Obinutuzumab and Venetoclax for the Treatment of Patients with Relapsed/refractory B Non-Hodgkin Lymphoma: Final Analysis of a Phase II Trial from the LYSA Group.
British journal of haematology(2025)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined